A Randomized Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer

Trial Profile

A Randomized Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Palbociclib (Primary) ; Bicalutamide; Goserelin; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Feb 2017 Results assessing feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer, presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top